22. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Non-Small Cell Lung Cancer. V3.2012. Available at www.NCCN.org.

23. Tsao M-S, Sakurada A, Cutz J-C, et al. Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-144.


Continue Reading

24. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64:8919-8923.

25. Sugio K, Uramoto H, Ono K, et al. Mutations within tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer. 2006;94:896-903.

26. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247-4253.

27. Sasaki T, Rodig SJ, Chirieac LR, Jånne PA. The biology and treatment of EML4-ALK non–small-cell lung cancer. Eur J Cancer. 2010;46(10):1773-1780.

28. Kwak EL, Bang Y-J, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer. N Engl J Med. 2010;363:1693-1703.

29. Li Y, Sheu C-C, Ye Y, et al. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010;11(4):321-330.

30. Li Y, Yang P. GPC5 gene and its related pathways in lung cancer. J Thorac Oncol. 2011;6(1):2-5.

31. Meguid RA, Hooker CM, Harris J, et al. Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer. Chest. 2010;138(3):500-509.

32. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukis D, Murray S. EGFR gene copy number as predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non–small-cell lung cancer. Ann Oncol. 2011;22:545-552.

33. Tsao AS, Liu D, Lee JJ, Spitz M, Kong WK. Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006;106;2428-2436.

34. Riely GJ, Pao W, Pham D, et al. Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2006;12:839-844.

35. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366(9496):1527-1537.

36. Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353:123-132.

37. Mok TW, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.

38. Janne PA, Wang XF, Socinski MA, et al. Randomized phase 2 trial of erlotinib alone or in combination with carboplatin/paclitaxel in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. J Clin Oncol. 2010;28(Suppl 15S):Abstract 7503.

39. Shaw AT, Yeap BY, Solomon GJ, et al. Impact of crizotinib on survival in patients with advanced ALK-positive NSCLC compared with historical controls. J Clin Oncol. 2011;29(15-May 20 Suppl):Abstract 7507.